Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2014-08-29 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
NON-COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES
Board/Management Information Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding non-compliance with Rule 3.10A of the Listing Rules of The Stock Exchange of Hong Kong Limited. It discusses the company's ongoing efforts to appoint an independent non-executive director to meet regulatory requirements. The content focuses on board composition and compliance with listing rules, specifically mentioning changes and appointments related to the board of directors. There are no financial statements, earnings data, or detailed management discussion. The document is not a full report but an announcement about board/management changes and compliance status. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Confidence is high due to clear references to board composition and regulatory compliance related to directors.
2014-08-29 English
EXCHANGE NOTICE - RESUMPTION OF TRADING
Regulatory Filings Classification · 95% confidence The document is a short notice from an exchange regarding the resumption of trading for a specific company's shares. It does not contain financial statements, management reports, or other substantive disclosures, but rather serves as a regulatory notification regarding market status. As it does not fit into specific categories like M&A or share issues, it falls under the general regulatory filing category.
2014-08-29 English
SALE OF EXISTING SHARES BY A SUBSTANTIAL SHAREHOLDER AND RESUMPTION OF TRADING
Capital/Financing Update Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding the sale of existing shares by a substantial shareholder and the resumption of trading. It details the placing agreement, shareholding percentages before and after the sale, lock-up period conditions, and the resumption of trading on the Hong Kong Stock Exchange. There are no financial statements, management discussion, or detailed financial data. The document is a regulatory announcement about a share sale and trading resumption, fitting the category of Capital/Financing Update (CAP). The length is about 5294 characters, which is sufficient for a full announcement rather than a brief note. Therefore, the appropriate classification is CAP with high confidence.
2014-08-29 English
TRADING HALT
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited regarding a trading halt on its shares due to pending release of inside information about a possible disposal of shares by the controlling shareholder. It is an announcement related to trading status and inside information, not a financial report, management change, or voting result. The document length is only 1338 characters, and it does not contain financial data or detailed report content. It is not a report publication announcement since it does not mention a report release. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2014-08-28 English
EXCHANGE NOTICE - TRADING HALT
Regulatory Filings Classification · 95% confidence The document is a short notice from an exchange regarding a trading halt for CSPC Pharmaceutical Group Limited. It does not fit into specific categories like earnings, dividends, or reports, and serves as a general regulatory announcement regarding market activity. Therefore, it falls under the RNS (Regulatory Filings) category.
2014-08-28 English
2014 INTERIM RESULTS ANNOUNCEMENT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2014 Interim Results Announcement' and contains detailed unaudited consolidated financial statements for the six months ended 30 June 2014, including profit and loss, financial position, segment information, notes on accounting policies, and income tax expenses. It references HKAS 34 Interim Financial Reporting and includes comprehensive financial data and analysis for a period shorter than a full fiscal year. The length of the document (15,000 characters) and the presence of substantive financial statements confirm it is a financial report, not merely an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2014
2014-08-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.